Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women

NCT00369343 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

381

Enrollment

INDUSTRY

Sponsor class

Conditions

Depression
Depressive Disorder
Depressive Disorder, Major

Interventions

DRUG: Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
DRUG: Placebo

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer